Literature DB >> 22145933

Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy.

John R Koethe1, Aihua Bian, Ayumi K Shintani, M Sean Boger, Valerie J Mitchell, Husamettin Erdem, Todd Hulgan.   

Abstract

Higher body mass index (BMI) is associated with increased serum C-reactive protein (CRP) levels in HIV-infected individuals on antiretroviral therapy (ART), but the relationship of adipose tissue mass to systemic inflammation is not well described in this population. We hypothesized that serum adipokine levels (i.e., hormones produced by adipocytes) are a superior predictor of CRP compared to anthropometric or radiographic measures of body composition in patients on effective, stable ART. We evaluated the relationship of serum leptin, adiponectin, and resistin, BMI, and dual energy x-ray absorptiometry (DEXA) measurements with serum highly sensitive CRP (hsCRP) in a cross-sectional cohort of 106 predominantly virologically suppressed, HIV-infected adults on ART for ≥24 weeks using multivariable linear regression and formal criteria to assess statistical mediation. Median BMI, hsCRP, and leptin values were 25.2 kg/m(2), 3.0 mg/liter, and 3.8 ng/ml, respectively. BMI and DEXA limb fat, body fat, and trunk fat measurements were significantly associated with both serum leptin and hsCRP levels (all p≤0.02). Leptin was also associated with hsCRP (p<0.01). The regression coefficient for the effect of BMI or DEXA measurements on hsCRP was reduced, and the relationship was no longer statistically significant, after adjusting for leptin, indicating leptin functioned as a mediating variable within these relationships. Adiponectin and resistin levels did not demonstrate similar effects. Serum leptin was a superior predictor of hsCRP compared to BMI and DEXA body fat measurements, which may reflect alterations in body composition in treated HIV infection and the important contribution of adipose tissue to inflammation in this population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22145933      PMCID: PMC3358098          DOI: 10.1089/aid.2011.0232

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  41 in total

1.  Distribution of C-reactive protein values in the United States.

Authors:  Steven Woloshin; Lisa M Schwartz
Journal:  N Engl J Med       Date:  2005-04-14       Impact factor: 91.245

2.  Fat distribution in men with HIV infection.

Authors:  Peter Bacchetti; Barbara Gripshover; Carl Grunfeld; Steven Heymsfield; Heather McCreath; Dennis Osmond; Michael Saag; Rebecca Scherzer; Michael Shlipak; Phyllis Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2005-10-01       Impact factor: 3.731

3.  Studies of body composition and fat distribution in HIV-infected and control subjects.

Authors:  D P Kotler; K Rosenbaum; J Wang; R N Pierson
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-03-01

4.  Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.

Authors:  Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

5.  Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.

Authors:  Handan Wand; Alexandra Calmy; Dianne L Carey; Katherine Samaras; Andrew Carr; Matthew G Law; David A Cooper; Sean Emery
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

6.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

7.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

Authors:  R V Considine; M K Sinha; M L Heiman; A Kriauciunas; T W Stephens; M R Nyce; J P Ohannesian; C C Marco; L J McKee; T L Bauer
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

8.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

9.  Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study.

Authors:  Michael S Boger; Ayumi Shintani; Leigh Anne Redhage; Valerie Mitchell; David W Haas; Jason D Morrow; Todd Hulgan
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

10.  Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study.

Authors:  Todd T Brown; Xiaoqiang Xu; Majnu John; Jaya Singh; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Joseph B Margolick; Adrian S Dobs
Journal:  AIDS Res Ther       Date:  2009-05-13       Impact factor: 2.250

View more
  6 in total

1.  Covariate-adjusted Spearman's rank correlation with probability-scale residuals.

Authors:  Qi Liu; Chun Li; Valentine Wanga; Bryan E Shepherd
Journal:  Biometrics       Date:  2017-11-13       Impact factor: 2.571

2.  An empirical comparison of two novel transformation models.

Authors:  Yuqi Tian; Torsten Hothorn; Chun Li; Frank E Harrell; Bryan E Shepherd
Journal:  Stat Med       Date:  2019-12-06       Impact factor: 2.373

3.  An association between adiposity and serum levels of macrophage inflammatory protein-1α and soluble CD14 in HIV-infected adults: results from a cross-sectional study.

Authors:  John R Koethe; Aihua Bian; Ayumi K Shintani; C William Wester; Husamettin Erdem; Todd Hulgan
Journal:  Antivir Ther       Date:  2013-06-07

4.  Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy.

Authors:  John R Koethe; Kevin Dee; Aihua Bian; Ayumi Shintani; Megan Turner; Sally Bebawy; Timothy R Sterling; Todd Hulgan
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-11       Impact factor: 2.205

5.  Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial.

Authors:  Catherine N Le; Todd Hulgan; Chi-Hong Tseng; Ginger L Milne; Jordan E Lake
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

6.  Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s.

Authors:  John R Koethe; Carlee Moser; Todd T Brown; James H Stein; Theodoros Kelesidis; Michael Dube; Judith Currier; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2022-03-09       Impact factor: 20.999

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.